Research indicates that semaglutide, used for weight loss in drugs like Ozempic and Wegovy, can also reduce alcohol intake. A randomized controlled trial involving 48 adults with alcohol use disorder demonstrated that those on semaglutide reduced their alcohol consumption by nearly 30% after two months, significantly more compared to a placebo group which saw only a 2% reduction. Participants on semaglutide also reported fewer days of heavy drinking and decreased cravings, highlighting a potential dual benefit of this medication beyond weight management.
Those who took semaglutide were drinking nearly 30 percent less, on average, on days they consumed alcohol compared to an average reduction of about two percent in the placebo group.
This is the first randomized controlled trial on semaglutide and alcohol consumption, showing significant reductions in alcohol cravings.
People who took semaglutide were also more likely to report fewer days of heavy drinking than those on the placebo.
The effects on alcohol consumption were larger than the researchers anticipated, given previous data on other medications for alcohol use disorder.
Collection
[
|
...
]